Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | PTAFR | P25105 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082563 | 0.81 | CYP4F2 (0.46) | CYP4F2CYP4A11MGLLHDAC6PTAFR | |
| SCHEMBL13097025 | 0.79 | DRD2 (0.49) | CYP4F2CYP4A11CHRNB2CHRNA4PTAFR | |
| SCHEMBL8765703 | 0.77 | DRD2 (0.60) | CHRNB2CHRNA4 | |
| SCHEMBL11071679 | 0.76 | CHRNA7 (0.53) | HRH1PTAFRTBXAS1 | |
| SCHEMBL21002079 | 0.75 | MGLL (0.68) | MGLLHDAC6 | |
| SCHEMBL26548204 | 0.75 | MGLL (0.68) | MGLLHDAC6 | |
| SCHEMBL8398287 | 0.75 | MGLL (0.68) | MGLLHDAC6 | |
| SCHEMBL16528761 | 0.75 | DRD2 (0.61) | CYP4F2CYP4A11CHRNB2CHRNA4 | |
| SCHEMBL22964344 | 0.74 | MAPK1 (0.58) | — | |
| SCHEMBL11232474 | 0.73 | DRD2 (0.68) | MGLLHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | CYP4F2 1907/4885CYP4A11 701/4885CHRNB2 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.